Most recurrences occurred in patients who had received prior chemotherapy , among whom the rate of freedom from breast cancer at @ years was @ % in the tamoxifen-ovarian suppression group and @ % in the tamoxifen group ( hazard ratio for recurrence , @ ; @ % CI , @ to @ ) .